Progress and controversies in the treatment of pancreatic neuroendocrine neoplasm

doi:10.3877/cma.j.issn.2095-3232.2024.05.002

Abstract

Abstract:

Pancreatic neuroendocrine neoplasm (pNEN) is a category of rare tumors with high heterogeneity. The treatment and management of pNEN are extremely complicated. Based on the latest guidelines and research progress at home and abroad, this article aims to discuss the hot topics and related controversies in the treatment of pNEN and propose the key points of future research, aiming to further promote the standardized treatment of pNEN.

Key words: Pancreatic neuroendocrine neoplasm, Surgical treatment, Treatment concept, Standardized treatment

Guihu Weng, Yueze Liu, Taiping Zhang. Progress and controversies in the treatment of pancreatic neuroendocrine neoplasm[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 602-606.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2024.05.002

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2024/V13/I05/602

References 39

[1]	Xu Z, Wang L, Dai S, et al. Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States[J]. JAMA Netw Open, 2021, 4(9):e2124750.
[2]	Lou X, Qin Y, Xu X, et al. Spatiotemporal heterogeneity and clinical challenge of pancreatic neuroendocrine tumors[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(5):188782.
[3]	de Ponthaud C, Menegaux F, Gaujoux S. Updated principles of surgical management of pancreatic neuroendocrine tumours (pNETs):what every surgeon needs to know[J]. Cancers, 2021, 13(23):5969.
[4]	中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)[J]. 中国癌症杂志, 2022, 32:545-580.
[5]	Maggino L, Schmidt A, Käding A, et al. Reappraisal of a 2 cm cut-off size for the management of cystic pancreatic neuroendocrine neoplasms: a multicenter international study[J]. Pancreatology, 2019, 19:S67-68.
[6]	Krogh S, Grønbæk H, Knudsen AR, et al. Predicting progression, recurrence, and survival in pancreatic neuroendocrine tumors: a single center analysis of 174 patients[J]. Front Endocrinol, 2022, 13: 925632.
[7]	Ricci C, Partelli S, Landoni L, et al. Survival after active surveillance versus upfront surgery for incidental small pancreatic neuroendocrine tumours[J]. Br J Surg, 2022, 109(8):733-738.
[8]	Giuliani T, De Pastena M, Paiella S, et al. Pancreatic enucleation patients share the same quality of life as the general population at long-term follow-up: a propensity score-matched analysis[J]. Ann Surg, 2023, 277(3):e609-616.
[9]	Bolm L, Nebbia M, Wei AC, et al. Long-term outcomes of parenchyma-sparing and oncologic resections in patients with nonfunctional pancreatic neuroendocrine tumors <3 cm in a large multicenter cohort[J]. Ann Surg, 2022, 276(3):522-531.
[10]	Titan AL, Norton JA, Fisher AT, et al. Evaluation of outcomes following surgery for locally advanced pancreatic neuroendocrine tumors[J]. JAMA Netw Open, 2020, 3(11):e2024318.
[11]	Heidsma CM, Tsilimigras DI, Rocha F, et al. Identifying risk factors and patterns for early recurrence of pancreatic neuroendocrine tumors: a multi-institutional study[J]. Cancers, 2021, 13(9):2242.
[12]	Hsu D, Le S, Chang A, et al. Should all pancreatic neuroendocrine tumors (PNET) over 1 cm be resected?[J]. J Clin Oncol, 2021, 39(15 Suppl):4108.
[13]	Tanaka M, Heckler M, Mihaljevic AL, et al. Systematic review and metaanalysis of lymph node metastases of resected pancreatic neuroendocrine tumors[J]. Ann Surg Oncol, 2021, 28(3):1614-1624.
[14]	Altimari M, Abad J, Chawla A. The role of oncologic resection and enucleation for small pancreatic neuroendocrine tumors[J]. HPB, 2021, 23(10):1533-1540.
[15]	Holmager P, Langer SW, Kjaer A, et al. Surgery in patients with gastro-entero-pancreatic neuroendocrine carcinomas, neuroendocrine tumors G3 and high grade mixed neuroendocrine-non-neuroendocrine neoplasms[J]. Curr Treat Options Oncol, 2022, 23(6):806-817.
[16]	Asano D, Kudo A, Akahoshi K, et al. Curative surgery and Ki-67 value rather than tumor differentiation predict the survival of patients with high-grade neuroendocrine neoplasms[J]. Ann Surg, 2022, 276(2):e108-113.
[17]	Raoul JL, Heymann MF, Dumont F, et al. Case report: grade 2 metastatic pancreatic neuroendocrine tumor with progression of one metastasis after pregnancy to grade 3 large-cell neuroendocrine carcinoma: one case cured by resection with genomic characterization of the two components[J]. Front Oncol, 2021, 11: 646992.
[18]	Pelosi G, Bianchi F, Dama E, et al. A subset of large cell neuroendocrine carcinomas in the gastroenteropancreatic tract may evolve from pre-existing well-differentiated neuroendocrine tumors[J]. Endocr Pathol, 2021, 32(3):396-407.
[19]	Mou Y, Wang ZY, Tan CL, et al. The role of primary tumor resection in patients with pancreatic neuroendocrine tumors with liver metastases[J]. Front Oncol, 2022, 12: 838103.
[20]	Yang Z, Liang J, Leng K, et al. Survival benefit of surgical resection for pancreatic neuroendocrine tumors with oligometastatic liver metastasis: a retrospective and propensity score-matching analysis[J]. Front Oncol, 2022, 12:903560.
[21]	You T, Tang H, Xu X, et al. Patients with non-functional metastatic G2 pancreatic neuroendocrine tumor benefit from palliative surgery: a 20-year single-center retrospective analysis[J]. J Neuroendocrinol, 2022, 34(12):e13211.
[22]	Kaemmerer D, Twrznik M, Kulkarni HR, et al. Prior resection of the primary tumor prolongs survival after peptide receptor radionuclide therapy of advanced neuroendocrine neoplasms[J]. Ann Surg, 2021, 274(1):e45-53.
[23]	Eshmuminov D, Studer DJ, Lopez Lopez V, et al. Controversy over liver transplantation or resection for neuroendocrine liver metastasis: tumor biology cuts the deal[J]. Ann Surg, 2023, 277(5):e1063-1071.
[24]	Hibi T, Rela M, Eason JD, et al. Liver transplantation for colorectal and neuroendocrine liver metastases and hepatoblastoma. working group report from the ILTS transplant oncology consensus conference[J]. Transplantation, 2020, 104(6):1131-1135.
[25]	Maspero M, Rossi RE, Sposito C, et al. Long-term outcomes of resection versus transplantation for neuroendocrine liver metastases meeting the Milan criteria[J]. Am J Transplant, 2022, 22(11):2598-2607.
[26]	Morizane C, Machida N, Honma Y, et al. Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial[J]. JAMA Oncol, 2022, 8(10):1447-1455.
[27]	Das S, Phillips S, Lee CL, et al. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - a systematic review and meta-analysis[J]. Eur J Cancer, 2023, 182:43-52.
[28]	Kunz PL, Graham NT, Catalano PJ, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)[J].J Clin Oncol, 2023, 41(7):1359-1369.
[29]	Li Y, Fan Z, Zhang F, et al. Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: a systematic review and meta-analysis[J]. Front Oncol, 2022, 12:981575.
[30]	吴峻立, 苗毅. 胰腺神经内分泌肿瘤肝转移术前评估和外科治疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(1):6-10.
[31]	Pusceddu S, Prinzi N, Tafuto S, et al. Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors[J]. JAMA Netw Open, 2022, 5(2):e220290.
[32]	Chiti G, Grazzini G, Flammia F, et al. Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a radiomic model to predict tumor grade[J]. Radiol Med, 2022, 127(9):928-938.
[33]	Javed AA, Pulvirenti A, Razi S, et al. Grading pancreatic neuroendocrine tumors via endoscopic ultrasound-guided fine needle aspiration: a multi-institutional study[J]. Ann Surg, 2023, 277(6):e1284-1290.
[34]	Liu C, Bian Y, Meng Y, et al. Preoperative prediction of G1 and G2/3 grades in patients with nonfunctional pancreatic neuroendocrine tumors using multimodality imaging[J]. Acad Radiol, 2022, 29(4):e49-60.
[35]	Wang M, Ding D, Qin T, et al. New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification[J]. Cancer Lett, 2021, 518:207-213.
[36]	Wang WQ, Zhang WH, Gao HL, et al. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors[J]. J Gastroenterol, 2021, 56(4):395-405.
[37]	Pulvirenti A, Javed AA, Landoni L, et al. Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors[J]. Ann Surg, 2021, 274(6):1051-1057.
[38]	Hua J, Shi S, Xu J, et al. Expression patterns and prognostic value of DNA damage repair proteins in resected pancreatic neuroendocrine neoplasms[J]. Ann Surg, 2022, 275(2):e443-452.
[39]	王先泽, 吴文铭. 胰腺神经内分泌肿瘤外科治疗理念的四种转变[J]. 中国癌症杂志, 2022, 32(9):765-771.

Please choose a citation manager

Content to export